soho2023
ELEVENTH ANNUAL MEETING

Global Perspectives on T-Cell Lymphoma. A proposed Road Map

T. Skrypets[1], M. Federico[2], F. Lemonnier[3], H. Tilly[4] on behalf of the European Lymphoma Institute

1Hematology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
2CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy
3Lymphoid malignancies unit, Henri Mondor hospital, Créteil, France
4Department of Hematology, Centre Henri Becquerel, Rouen, France

INTRODUCTION

Regardless the continuous efforts of researchers involved in the field of the continuous efforts of researchers, peripheral T-cell lymphomas (PTCLs) are an orphan group of lymphoproliferative disorders that need more attention and care.

OBJECTIVE

PTCLs have mostly clinically aggressive disease courses, and they constitute about 10-15% of all non-Hodgkin's lymphoma (NHL) in Western countries, with an overall incidence of 0.5-2/100,000 people/year and 15-20% of all NHLs in Asia. The preceding international data and experience have vividly highlighted many substantial challenges associated with incredible heterogeneity, extraordinary rarity, advanced problems in the therapeutical approaches, and care of patients with
PTCLs.

PARTICIPANTS

The European Lymphoma Institute (ELI), regroups European specialists dedicated to research, training, and education in lymphoma. To date, thirteen European academic research groups have come together to define strategies for better analyzing and characterizing lymphomas, common diagnostic procedures and therapeutic standards, as well as to facilitate clinical, translational and basic research, education and knowledge sharing at the European level.

RESULTS

On September 29-30, 2022, ELI held a workshop on "T-cell lymphoma in Europe". The main aim of this meeting was to discuss the most emerging questions and future perspectives in epidemiology, diagnosis and classification of PTCLs, together with controversies in frontline treatment ("is CHOP a good backbone" and "utility of upfront ASCT"), immunotherapy and other novel approaches (preclinical models, PD1 blockage, epigenetic targets and CAR-T challenges).

CONCLUSIONS

The conclusion of these two days of very fruitful discussions was that there are still a lot of urgent unmet needs and open questions in PTCLs management worldwide. A list of priorities is proposed in Table 1, including the prospective collection of data to better understand the clinical and practical relevance of the new WHO classification, the prognosis and the genomic landscape of different subtypes, the role of imaging (FDG-PET, radiomic futures) and ctDNA analysis in staging, response assessment and relapse prediction. Moreover, it confirmed the urgency for promoting further efforts in investigating the most adequate and appropriate treatment strategies trough the conduction of well-designed clinical trials and deep analysis of the outcome of patients with PTCLs in the real world.

ACKNOWLEDGEMENTS

1. European Lymphoma Institute and all academic groups

2. Associazione Angela Serra per la Ricerca sul Cancro

Table 1. A list of proposed priorities

EMERGING QUETSIONS
1. Perspective in Epidemiology, Diagnosis, and Classification
2. Controversies in frontline treatment:
• the more appropriate backbone
• upfront ASCT
3. Immunotherapy and other novel approaches

PROPOSED PRIORITIES
• prospective collection of data
• clinical and practical relevance of the new WHO classification
• prognosis of different entities
• the genomic landscape of different subtypes
• the role of imaging (FDG-PET, radiomic futures) and ctDNA analysis in staging, response assessment and relapse prediction
• promoting further efforts in investigating the most adequate and appropriate treatment strategies, trough the conduction of well-designed clinical trials and a deep analysis on the outcome of patients with PTCLs in the real world.

CONTACT INFORMATION

Tetiana Skrypets

tetianaskrypets@gmail.com